改良髓芯减压术联合骨形态发生蛋白活性诱导棒植入术治疗早期股骨头缺血性坏死的临床观察OA

Objective:To observe the clinical efficacy of early-stage avascular necrosis of the femoral head(ANFH)using modified porous core decompression combined with implantation of a bone morphogenetic protein-activating rod.Methods:From May 2022 to June 2024,80 patients with early ANFH who received medical treatment were grouped into the decom-pression group(40 cases,adopted improved porous core decompression)and the joint group(40 cases,adopted improved porous core decompression+bone morphogenetic protein activity induction rod implantation)complying with the treat-ment method.Two groups were compared in terms of postoperative clinical efficacy,perioperative indicators,pain visual analogue scale(VAS)score,Harris hip score,bone metabolism markers,and postoperative complications.Results:After surgery,the joint group had an excellent or good rate of 92.50%(37/40),which was significantly higher than that of the decompression group 75.00%(30/40)(P<0.05).Both groups showed a decrease in VAS scores after surgery,with the joint group exhibiting significantly lower scores than the decompression group(P<0.05).Both groups had clearly increased Harris score((86.32±18.38)points vs(78.14±15.25)points),osteocalcin(OC),and bone morphogenetic protein-2(BMP-2)after surgery,with the joint group being clearly higher than the decompression group(P<0.05).For the joint group,the decompression group had significantly shorter surgical time((62.12±7.10)min vs(52.12±6.20)min)and less intraoperative bleeding((132.10±15.60)mL vs(102.31±12.30)mL)(P<0.05).The postoperative complications were not clearly different between two groups(P>0.05).Conclusion:The joint use of improved porous core decompression with bone morphogenetic protein activity in-duction rod implantation for ANFH can improve the excellent rate of patients.It can reduce VAS score,improve Harris hip score and bone metabolism,and has high safety.